8-K: Telomir Pharmaceuticals Appoints Alan Weichselbaum as CFO, Announces Departure of Michelle Yanez

Telomir Pharmaceuticals announces the appointment of Alan Weichselbaum as Chief Financial Officer, effective May 15, 2025, following the mutual separation of Michelle Yanez from the same role.

Summary

• Telomir Pharmaceuticals announced the mutual separation of Michelle Yanez from her position as Chief Financial Officer, Treasurer, and Secretary, effective May 16, 2025.
• Alan Weichselbaum was appointed as the new Chief Financial Officer, effective May 15, 2025.
• Mr. Weichselbaum brings over 30 years of experience in corporate finance, capital markets, and strategic advisory.
• He will receive an annual salary of $60,000 and is eligible for options to purchase 50,000 shares of the company's common stock.
• 25,000 of the options will vest six months after the start date (May 19, 2025), and another 25,000 will vest twelve months after the start date, contingent upon continued employment.

Sentiment

Score: 7

Explanation: The announcement is generally positive due to the appointment of an experienced CFO. However, the part-time nature of the role and the departure of the previous CFO introduce some uncertainty.

Positives

• Alan Weichselbaum brings extensive experience in corporate finance and capital markets to Telomir Pharmaceuticals.
• His background includes roles in hedge funds, investment banking, and as CFO of MIRA Pharmaceuticals, Inc.
• The employment agreement includes an option grant, incentivizing Mr. Weichselbaum to contribute to the company's success.
• The company has secured a seasoned financial professional to guide its financial strategy.

Negatives

• The departure of Michelle Yanez as CFO creates a transition period.
• The new CFO's role is part-time, requiring 30 hours per week, which may impact the level of engagement.

Risks

• The success of the option grant depends on Mr. Weichselbaum's continued employment with the company.
• The company's future performance is subject to the standard risks associated with drug development, licensing, and M&A activities.
• The company's ability to retain Mr. Weichselbaum is subject to the at-will employment agreement.

Future Outlook

The company aims to advance its financial and strategic objectives through drug development, licensing, and potential M&A opportunities with Alan Weichselbaum as CFO.

Management Comments

• The document does not contain direct quotes, but it highlights that Alan Weichselbaum's deep financial acumen, combined with extensive experience in investor relations, capital formation, and M&A, makes him a vital member of the executive leadership at Telomir Pharmaceuticals, Inc.

Industry Context

The appointment of a new CFO is a common occurrence in the pharmaceutical industry, especially for companies undergoing growth or strategic changes. Alan Weichselbaum's experience in capital markets and M&A suggests that Telomir Pharmaceuticals may be positioning itself for potential transactions or further development.

Comparison to Industry Standards

• CFO compensation in small-cap pharmaceutical companies typically includes a base salary and stock options, aligning with the structure of Alan Weichselbaum's compensation package.
• Part-time CFO roles are not uncommon for companies in early stages of development or those seeking specialized expertise without the need for a full-time commitment.
• Comparable companies might include other small-cap biotech firms listed on Nasdaq, such as MIRA Pharmaceuticals, where Mr. Weichselbaum also serves as CFO.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of an experienced CFO positively.
• Employees may experience a transition period with the change in financial leadership.
• The company's financial strategy and potential M&A activities could impact suppliers and creditors.

Next Steps

• Alan Weichselbaum will commence his role as CFO on May 19, 2025.
• The Board of Directors will determine the exercise price for the stock options.
• Mr. Weichselbaum will be required to sign the company's standard Proprietary Information and Inventions Agreement.

Key Dates

Keywords

Chief Financial Officer, CFO, Alan Weichselbaum, Michelle Yanez, Telomir Pharmaceuticals, Appointment, Resignation, Employment Agreement, Options, Corporate Finance